Good MorningEquities started the week on positive footing with the S&P 500 index moving up slightly to set a new all-time high. Monday’s action marks the 12th positive close in three weeks for the index and could easily lead to another string of new highs. The move is driven by corporate earnings that have come in better than expected despite strong headwinds within the economy. This week, traders will on alert for reports from another 167 S&P 500 companies marking the busiest week of the reporting season. By the end of this week, nearly 90% of the index will have reported results for the season.
Also on tap this week, a key meeting of the FOMC and the monthly NFP report. The FOMC is expected to begin tapering or explain why they are waiting while the NFP is expected to be a tepid 450,000. After last months’ decline in total unemployment claims, the NFP figure should run well into the millions.
Featured: He Predicted the iPhone Years Before It Existed (Ad) 
|
Consumer Staples | |
Price Hikes Push The Clorox Company Higher
The Clorox Company (NYSE: CLX) is a poster child for both the pandemic and post-pandemic worlds. The company saw a 500% increase in demand for its products that outpaced expectations during both the spike and decline that has shares trading at their low... Read the Full Story |
|
|
Technology | | Shares of monday.com (NASDAQ: MNDY) are consolidating above key moving averages below a September 2 high of $425.84.
It’s one of several enterprise-focused software applications showing technical strength right now.
Rivals including Atlassian (NASDAQ: TEAM) and Asana (NYSE: ASAN) also boas... Read the Full Story |
|
Markets | | Small-cap Brigham Minerals (NYSE: MNRL) is trading in new high ground ahead of the company's third-quarter earnings report after the market close on Wednesday.
The company will host its earnings conference call on Thursday at noon Eastern.
The stock has been on the rise since the week ended Septem... Read the Full Story |
|
From Our Partners | | Nearly 2 in 3 Americans fear running out of money more than death - and chasing a $1.5 million nest egg isn't helping.
Tim Plaehn has spent decades helping people build retirement income, and he says the monthly income goal is the only number that matters. His approach could potentially reach that goal with 10x less capital - using a single stock you can buy with one click. | | Watch the short presentation to see how this retirement income strategy works |
|
Consumer Discretionary | |
As we learned with Starbucks’ (NASDAQ:SBUX) recent quarterly report, sometimes even record sales aren’t enough. The popular coffee shop operator delivered its best fourth-quarter result ever last week, but the news failed to energize the market.
In fact, the opposite occurred. The upd... Read the Full Story |
|
Industrials | | Hydrogen fuel cell technology provider Plug Power (NASDAQ: PLUG) stock is getting a second wind as it rises after losing more than (-60%) from its 2021 highs of $75.49. The hydrogen fuel cell pioneer’s energy technology is being validated through partnerships with many large companies includin... Read the Full Story |
|
From Our Partners | If you've saved over $1,000,000, the challenge shifts from building wealth to making it last through retirement.
Fisher Investments' Definitive Guide to Retirement Income outlines seven strategies wealthy retirees use to generate lasting income. Since 1979, the firm has helped tens of thousands of investors retire comfortably, managing over $441 billion in assets. | | Download the free retirement income guide from Fisher Investments today |
|
Markets | |
Have you ever heard the story of the grandma, the little girl and the pot roast?
A little girl watches as her mom cuts off both ends of a chuck roast before she puts it into the roasting pan.
Watching her mom throw both ends of the roast away, the little girl says to her mom, "Why do you cut o... Read the Full Story |
|
Communication Services | | Streaming platform and hardware provider Roku (NASDAQ: ROKU) stock has been selling off as streaming content providers are start pushing back. The blowback from the fallout with YouTube TV (NASDAQ: GOOG) is spreading to other content providers. Amazon Prime (NASDAQ: AMZN) is next up for negotiating ... Read the Full Story |
|
Industrials | |
Supply-Chain Specialist ArcBest Boosted By Demand
Anyone surprised by ArcBest Corporation’s (NASDAQ: ARCB) Q3 results isn’t paying attention to the freight market. ArcBest Corporation operates as an integrated trucking outfit with specialization in LTL, supply-chain logistics, and in... Read the Full Story |
|
Utilities | |
American Water Works (NYSE:AWK) will deliver its third-quarter earnings report after the market closes on November 2. The third quarter has historically been the company’s strongest quarter and this year appears to be no exception.
The consensus opinion of analysts is for the utility gian... Read the Full Story |
|
Technology | |
ON Semiconductors Breaks Out To New Highs
Shares of ON Semiconductors (NASDAQ: ON) are breaking out to new highs following the Q3 earnings report. The company, as an American-based manufacturer of semiconductor solutions, was expected to report strong numbers and it did. More importantly, the co... Read the Full Story |
|
The Early Bird Stock Of The Day Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation. | | View Today's Stock Pick |
|
